Biologic and Small Molecule Treatment for Seborrheic Dermatitis: An Evidence-Based Review

Abstract

Keywords

seborrheic dermatitis biologic Janus kinase inhibitor phosphodiesterase-4 small molecule systematic review

Get full access to this article

View all access options for this article.

References

Jackson

Alexis

Zirwas

Taylor

. Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol. 2024;90(3):597-604. doi:10.1016/j.jaad.2022.12.017

Sparber

De Gregorio

Steckholzer

, et al The skin commensal yeast malassezia triggers a type 17 response that coordinates anti-fungal immunity and exacerbates skin inflammation. Cell Host Microbe. 2019;25(3):389.e6-403.e6. doi:10.1016/j.chom.2019.02.002

Adalsteinsson

Kaushik

Muzumdar

Guttman-Yassky

Ungar

. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol. 2020;29(5):481-489. doi:10.1111/exd.14091

Blauvelt

Draelos

Stein Gold

, et al Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: a randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol. 2024;90(5):986-993. doi:10.1016/j.jaad.2023.12.065

Ruxolitinib in seborrheic dermatitis. ClinicalTrials.gov identifier: NCT05787860. Updated March 26, 2024. Accessed July 31, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT05787860

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.32 MB

0.02 MB

0.03 MB